The Impact of Subthalamic Deep Brain Stimulation on Nigral Neuroprotection—Myth or Reality?
Identifieur interne : 000527 ( Main/Exploration ); précédent : 000526; suivant : 000528The Impact of Subthalamic Deep Brain Stimulation on Nigral Neuroprotection—Myth or Reality?
Auteurs : Daniel Harnack [Allemagne] ; Andreas Kupsch [Allemagne]Source :
- Neuromodulation: Technology at the Neural Interface [ 1094-7159 ] ; 2010-07.
English descriptors
- KwdEn :
Abstract
Objective: In the present review article we summarize available clinical and preclinical evidence, if modulation of the subthalamic nucleus (STN) could be a target for neuroprotection in Parkinson's disease (PD). Background: Chronic deep brain stimulation (DBS) of the STN has emerged as a powerful therapeutic alternative for the treatment of PD, ensuring stable symptom control for up to five years despite the progressive nature PD. Materials and Methods: Comparative review of literature in PuBMed available up to December 2008. Results: The assessment of neuroprotection has been proven difficult in the clinical situation, as medical or surgical therapeutic options that improve PD symptoms could be erroneously considered to be neuroprotective because of the difficulty of differentiating between symptomatic effects and potential neuromodulative disease‐related effects of various treatment options applied in PD. The methodological limitations of clinical trials underline the importance of putative neuroprotective compounds to be tested in clinically driven preclinical studies. Thus, animal models, mimicking progressive nigrostriatal cell death, are indispensable to further advance the important issue of neuroprotection or neuromodulation following DBS. Conclusion: Clear clinical evidence for STN‐DBS‐related neuroprotection in PD is missing. However, numerous preclinical studies show (and are discussed) that silencing of the STN via lesion or DBS may exert neuromodulative effects on nigral dopamine neurons.
Url:
DOI: 10.1111/j.1525-1403.2010.00282.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Impact of Subthalamic Deep Brain Stimulation on Nigral Neuroprotection—Myth or Reality?</title><author><name sortKey="Harnack, Daniel" sort="Harnack, Daniel" uniqKey="Harnack D" first="Daniel" last="Harnack">Daniel Harnack</name></author><author><name sortKey="Kupsch, Andreas" sort="Kupsch, Andreas" uniqKey="Kupsch A" first="Andreas" last="Kupsch">Andreas Kupsch</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0278460DA67C74FFAE345DB94A294D692118618D</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1111/j.1525-1403.2010.00282.x</idno><idno type="url">https://api.istex.fr/document/0278460DA67C74FFAE345DB94A294D692118618D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000B22</idno><idno type="wicri:Area/Main/Curation">000980</idno><idno type="wicri:Area/Main/Exploration">000527</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The Impact of Subthalamic Deep Brain Stimulation on Nigral Neuroprotection—Myth or Reality?</title><author><name sortKey="Harnack, Daniel" sort="Harnack, Daniel" uniqKey="Harnack D" first="Daniel" last="Harnack">Daniel Harnack</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Charité, University Medicine Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Kupsch, Andreas" sort="Kupsch, Andreas" uniqKey="Kupsch A" first="Andreas" last="Kupsch">Andreas Kupsch</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Charité, University Medicine Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Neuromodulation: Technology at the Neural Interface</title><idno type="ISSN">1094-7159</idno><idno type="eISSN">1525-1403</idno><imprint><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2010-07">2010-07</date><biblScope unit="volume">13</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="160">160</biblScope><biblScope unit="page" to="167">167</biblScope></imprint><idno type="ISSN">1094-7159</idno></series><idno type="istex">0278460DA67C74FFAE345DB94A294D692118618D</idno><idno type="DOI">10.1111/j.1525-1403.2010.00282.x</idno><idno type="ArticleID">NER282</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1094-7159</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>High frequency stimulation</term><term>Parkinson's disease</term><term>microstimulator</term><term>movement disorders</term><term>neurostimulation</term><term>rats</term><term>stimulator</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: In the present review article we summarize available clinical and preclinical evidence, if modulation of the subthalamic nucleus (STN) could be a target for neuroprotection in Parkinson's disease (PD). Background: Chronic deep brain stimulation (DBS) of the STN has emerged as a powerful therapeutic alternative for the treatment of PD, ensuring stable symptom control for up to five years despite the progressive nature PD. Materials and Methods: Comparative review of literature in PuBMed available up to December 2008. Results: The assessment of neuroprotection has been proven difficult in the clinical situation, as medical or surgical therapeutic options that improve PD symptoms could be erroneously considered to be neuroprotective because of the difficulty of differentiating between symptomatic effects and potential neuromodulative disease‐related effects of various treatment options applied in PD. The methodological limitations of clinical trials underline the importance of putative neuroprotective compounds to be tested in clinically driven preclinical studies. Thus, animal models, mimicking progressive nigrostriatal cell death, are indispensable to further advance the important issue of neuroprotection or neuromodulation following DBS. Conclusion: Clear clinical evidence for STN‐DBS‐related neuroprotection in PD is missing. However, numerous preclinical studies show (and are discussed) that silencing of the STN via lesion or DBS may exert neuromodulative effects on nigral dopamine neurons.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Berlin</li></region><settlement><li>Berlin</li></settlement></list><tree><country name="Allemagne"><region name="Berlin"><name sortKey="Harnack, Daniel" sort="Harnack, Daniel" uniqKey="Harnack D" first="Daniel" last="Harnack">Daniel Harnack</name></region><name sortKey="Kupsch, Andreas" sort="Kupsch, Andreas" uniqKey="Kupsch A" first="Andreas" last="Kupsch">Andreas Kupsch</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000527 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000527 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0278460DA67C74FFAE345DB94A294D692118618D
|texte= The Impact of Subthalamic Deep Brain Stimulation on Nigral Neuroprotection—Myth or Reality?
}}
| This area was generated with Dilib version V0.6.23. |  |